80 related articles for article (PubMed ID: 16885561)
41. BRCA2-associated therapy-related acute myeloid leukemia.
Rashidi A; Amarillo I; Fisher SI
Med Oncol; 2015 Jan; 32(1):371. PubMed ID: 25428384
[No Abstract] [Full Text] [Related]
42. The Sweet syndrome during therapy with granulocyte colony-stimulating factor.
Park JW; Mehrotra B; Barnett BO; Baron AD; Venook AP
Ann Intern Med; 1992 Jun; 116(12 Pt 1):996-8. PubMed ID: 1375012
[No Abstract] [Full Text] [Related]
43. Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number.
Ferretti G; Papaldo P
Ann Oncol; 2007 Jun; 18(6):1118-9. PubMed ID: 17586752
[No Abstract] [Full Text] [Related]
44. Acute promyelocytic leukemia in a young patient with breast cancer.
Kara O; Ozdemir E; Arslan C; Dogan E; Altundag K
Med Oncol; 2011 Mar; 28(1):249-50. PubMed ID: 20140540
[No Abstract] [Full Text] [Related]
45. Myeloid-positive T cell acute leukemia after treatment of infantile neuroblastoma.
Ayukawa H; Umemoto Y; Kawasaki K; Koga M; Furukawa S; Ikuno Y
Med Pediatr Oncol; 2001 Nov; 37(5):479-80. PubMed ID: 11745880
[No Abstract] [Full Text] [Related]
46. Breast cancer and leukemia: the forest for the trees?
Hudis C
Ann Surg Oncol; 2002 Oct; 9(8):717-8. PubMed ID: 12374652
[No Abstract] [Full Text] [Related]
47. [Pancytopenia and macular rash in a woman with a history of breast cancer].
Jacobi D; Vidal C; Gironet N; Machet MC; Machet L
Rev Med Interne; 2003 Jun; 24(6):399-400. PubMed ID: 12814830
[No Abstract] [Full Text] [Related]
48. Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Philpott NJ; Bevan DH; Gordon-Smith EC
Lancet; 1993 May; 341(8855):1289. PubMed ID: 8098437
[No Abstract] [Full Text] [Related]
49. Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee.
Marty M
J Clin Oncol; 1993 Jul; 11(7):1431-3. PubMed ID: 8369062
[No Abstract] [Full Text] [Related]
50. Therapy-related leukemia: what is the role of 4-epi-doxorubicin?
Riggi M; Riva A
J Clin Oncol; 1993 Jul; 11(7):1430-1. PubMed ID: 8315440
[No Abstract] [Full Text] [Related]
51. Increase therapy-related leukemia secondary to breast cancer.
Carli PM; Sgro C; Parchin-Geneste N; Isambert N; Mugneret F; Girodon F; Maynadié M
Leukemia; 2000 Jun; 14(6):1014-7. PubMed ID: 10865966
[TBL] [Abstract][Full Text] [Related]
52. Reply to E.J. Moylan et al.
Swain SM; Tang G; Geyer CE
J Clin Oncol; 2014 Feb; 32(6):606-7. PubMed ID: 24419136
[No Abstract] [Full Text] [Related]
53. Pseudoleukemia following the use of G-CSF.
Reykdal S; Sham R; Phatak P; Kouides P
Am J Hematol; 1995 Jul; 49(3):258-9. PubMed ID: 7541606
[No Abstract] [Full Text] [Related]
54. Hematopoietic growth factors in breast cancer--overview.
Osborne CK
Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S1-2. PubMed ID: 1806028
[No Abstract] [Full Text] [Related]
55. G-CSF could worsen anaemia in breast cancer.
Furlow B
Lancet Oncol; 2006 Aug; 7(8):622. PubMed ID: 16900597
[No Abstract] [Full Text] [Related]
56. Modifying risks of secondary leukemias: is drug scheduling important?
Karp JE; Smith MA
J Natl Cancer Inst; 1996 Dec; 88(24):1787-9. PubMed ID: 8961963
[No Abstract] [Full Text] [Related]
57. DNA repair and the risk of secondary leukemias.
Gerson SL
J Clin Oncol; 1996 Feb; 14(2):681-2. PubMed ID: 8636789
[No Abstract] [Full Text] [Related]
58. Secondary leukaemia after epipodophyllotoxins.
Hawkins MM
Lancet; 1991 Nov; 338(8779):1408. PubMed ID: 1682778
[No Abstract] [Full Text] [Related]
59. Lineage-specific hematopoietic growth factors.
Dale DC; Rosenberg PS; Alter BP
N Engl J Med; 2006 Aug; 355(5):526-7; author reply 527. PubMed ID: 16888846
[No Abstract] [Full Text] [Related]
60. Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches.
Zhang L; Mack R; Breslin P; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):157. PubMed ID: 33228751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
